Medication counterfeiting has substantial social and economic drawbacks. Most notably, buyers do not get the safe-to-use and/or efficient drugs they paid for and in many cases, may be put in a life threatening position, which can result in massive client loss.
On the financial side, genuine medication producers carry the burden of patent and copyright violation. Moreover, forgers take full benefit of the fact that somebody else spent resources on R&D expenditures.
In 2006, according to official World Health Organization (WHO) reports, drug counterfeiting represented approximately $45 billion euros in sales, almost 10% of the market at that time. By 2010, worldwide drug counterfeiting generated an estimated $75 billion, according to the American Centre for Medicine in the Public Interest. This number is likely to grow.
In response to this massive loss in sales and market share, Neutroplast is aiming to help laboratories keep their products safe, by protecting their drugs from illegal markets. New measures will not only help laboratories better control their products, they will also help to avoid major social health issues.
With Neutroplast's new anti-counterfeiting print service, all products can be easily identified and of course traced back to the original producer. Brands can use this service to "equip" their products with proof of authenticity, and instantly make them more reliable, from a buyer's perspective. Companies can also avoid direct money loss resulting from reduced market share, decreases in sales, and resources spent on legal services in order to solve counterfeiting.
